Effect of Protocol-Based Pharmacotherapy Management on Rubella Vaccination in Puerperal Women with Low Rubella Antibody Titer

Postpartum rubella vaccination is recommended for puerperal women with low rubella antibody titer to prevent congenital rubella syndrome. We have constructed a protocol-based pharmacotherapy management (PBPM) that contributes to the efficiency and safety of rubella vaccination, and we report the results. The ward pharmacist identified a puerperal woman with low rubella antibody titer, provided drug guidance regarding the rubella vaccine to that person, and requested a doctor to prescribe it. When identifying the subjects, it was confirmed whether or not they were inappropriate for vaccination as described in the package insert of the rubella vaccine. The subjects were puerperal women who gave birth at our hospital from April 1, 2017 to March 30, 2020. The vaccination rate (56.7 ％ ) after the introduction of PBPM was not significantly different from that when led by a doctor (60.0 ％ ). The vaccination avoidance rate for those who were unsuitable for rubella vaccination was 71.4 ％ (5/7) before the introduction of PBPM, and 100.0 ％ (9/9) after the introduction of PBPM. Intervening after confirming the package insert is considered to be the work of the pharmacist from the viewpoint of drug management. The introduction of PBPM not only reduces the burden on doctors, but also avoids the health hazards of the rubella vaccine and the inadequate effectiveness of the vaccine, which is considered to be a significant initiative.